Jun 27 |
With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors
|
Jun 24 |
Entrada Therapeutics announces $100M registered direct offering
|
Jun 24 |
Entrada Therapeutics Announces $100 Million Registered Direct Offering
|
Jun 24 |
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
|
Jun 16 |
Entrada Therapeutics: A Complicated Tale
|
Jun 3 |
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
|
May 21 |
Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet
|
May 16 |
Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)
|
May 16 |
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
|
May 8 |
Entrada Therapeutics First Quarter 2024 Earnings: Beats Expectations
|